We investigated the clinical and photographic characteristics of uremic lung and review the associated literature, so as to improve the diagnostic and therapeutic abilities of uremic lung. The clinical symptoms and signs together with the photographic characteristics of the patient who was diagnosed as uremic lung complicated with pulmonary infection and congestive heart failure in our division were analysed and the associated literature was reviewed. The patient was admitted for the complaint of cough, expectoration and dyspnea. He was diagnosed as chronic renal failure with pulmonary infection and congestive heart failure. The symptoms alleviated after adequate hemodialysis and antibiotic therapy. However, mild dyspnea remained with photographic examination still showing consolidation in the lungs. The diagnosis of uremic lung was established after the exclusion of pulmonary infections of other pathogens and tumor. After 8-month maintenance hemodialysis, the pulmonary lesions were thoroughly absorbed. Uremic lung is a common complication of end-stage renal failure. The diagnosis is established after the exclusion of cardiac pulmonary edema, pulmonary infections and tumors. Sufficient hemodialysis is the most adequate treatment for uremic lung.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Microangiopathic Hemolytic Anemia as the Initial Presentation of Metastatic Signet-Ring Cell Carcinoma of the Colon: A Case Report.
Cureus
December 2024
Internal Medicine, Hurley Medical Center, Flint, USA.
Microangiopathic hemolytic anemia (MAHA) is a condition characterized by intravascular fragmentation of red blood cells, leading to the characteristic finding of schistocytes on a peripheral blood smear. The differential diagnoses of MAHA include thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), disseminated intravascular coagulation (DIC), idiopathic thrombocytopenic purpura (ITP), infections, malignancies, and solid organ transplantation. The commonly associated malignancies with MAHA are gastric, breast, prostate, lung, and lymphoma.
View Article and Find Full Text PDFOutcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: A systematic literature review.
Transfus Apher Sci
December 2024
Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA. Electronic address:
Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019-2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, 'typical' hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined.
View Article and Find Full Text PDFCalcific Uremic Arteriolopathy (CUA) Among Malaysian Dialysis Patients: Clinical Characteristics, Treatment, and Outcomes.
Cureus
November 2024
Department of Nephrology, Universiti Malaya Medical Centre, Kuala Lumpur, MYS.
Background Calcific uremic arteriolopathy (CUA) is a rare but debilitating disease affecting patients with kidney disease. Reported risk factors of CUA in the literature include female sex, obesity, diabetes mellitus, and vitamin K antagonists' (VKAs) usage. CUA prevalence in Malaysia is unknown and has not been reported before.
View Article and Find Full Text PDFA real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab.
Expert Opin Drug Saf
December 2024
Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Fuzhou, PR China.
Background: Ramucirumab (IMC-1121B) is a fully human immunoglobulin G1 monoclonal antibody, approved by the US Food and Drug Administration (FDA) for treating various cancers, including gastric, colorectal, liver, and non-small cell lung cancer. This study aimed to investigate the adverse events (AEs) associated with ramucirumab by utilizing data mining techniques on the FDA Adverse Event Reporting System (FAERS).
Methods: We collected ramucirumab-related data from the FAERS database, spanning from January 2014 to June 2023.
[Thrombotic microangiopathy as a rare complication after lung transplantation].
Praxis (Bern 1994)
October 2024
Klinik für Pneumologie, Universitätsspital Zürich, Rämistrasse 100, CH-8091 Zürich.
Thrombotic microangiopathy (TMA) is defined by the typical triad of severe thrombocytopenia, hemolytic anemia and endorgan dysfunction and can be characterized by the pathophysiology of ischemia-inducing microthrombi in arterioles and capillaries possibly leading to severe organ dysfunction up to acutely life-threatening endorgan damage. In terms of etiology, management, therapy and prognosis, the following manifestations are distinguished: thrombotic thrombocytopenic purpura (TTP), shigatoxin-induced hemolytic-uremic syndrome (STEC-HUS), secondary comorbidity-related TMA and atypical hemolytic-uremic syndrome (aHUS). We present the case of a 49 year old lung transplant recipient developing aHUS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!